Business Layout

CN EN

Stock code: 002653.SZ

Home

News

Innovation

Pipeline R&D Platforms

Products

Product List Product Topics Pharmacovigilance

Investors

Stock Information Company Announcements Market Data Q&A Investor Hotline

Join Us

Talent Philosophy Careers

About Haisco

About Us Business Presence

GLOBAL

English China

Production Base

With production capacity as a wingThings needed to maintain health

Haisco (Sichuan)

Designated as a R&D-driven production base, it involves the development of active pharmaceutical ingredients in multiple fields such as cardiovascular, anti-infection, digestive system, mental system, liver disease, and metabolic system, pilot scale up, production of clinical samples, and commercial production of raw materials and auxiliary materials.

Haisco (Meishan)

Meihai, as the commercial production base for the group's non-sterile active pharmaceutical ingredients and solid preparations, has multiple production lines for tablets, capsules, granules, ointments, creams, and active pharmaceutical ingredients. Its products are used in various fields such as the mental system, digestive system, anti-infection, liver disease, anesthesia, and blood system. It also serves as the conversion center for the group's formulation and active pharmaceutical ingredient research and development projects to achieve commercial production. It provides strong support for the group in overcoming technical barriers during process scaling.

Haisco (Shenyang)

Shenyang Haisco Pharmaceutical Co., Ltd. was established in 2015. It is the core production base of Haisco Pharmaceutical Group's strategic layout in the Northeast region. The company has standardized office buildings, production facilities, and supporting infrastructure that have passed national GMP certification. It also has three sterile product production workshops, including lines for large-volume injectables (glass vials, non-PVC multi-layer co-extruded soft bags) and small-volume injectables. Focusing on areas such as anesthesia and analgesia, and parenteral nutrition, the company has obtained 5 invention patents and 9 utility model patents. It has received production approvals for 3 products in 5 specifications, including the first Chinese 1-class innovative intravenous anesthetic—cetanorpholine injection, fat emulsion amino acids (17) glucose (11%) injection, and compound amino acid injection (18AA-VII) among other flagship products.

Haisco (Liaoning)

It has 9 professional production lines for small-volume injections, large-volume injections, frozen dry powder injections, and powder injections.

Haisco (Tibet)

Tibet Haisco Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the group. Established in 2019, it combines drug research and development with production. Its main products include tablets, granules, and hard capsules. It is the first modern chemical preparation production base in the Tibet Autonomous Region to be built and put into operation. Currently, it has a comprehensive production line for oral solid preparations with an annual output of 10,000 million tablets, focusing on the production of lapatanide fumarate tablets.

ton/year

The non-sterile active pharmaceutical ingredients production line equipped on this line has a designed annual production capacity of 5 tons, which can reliably meet the market demand for related non-sterile active pharmaceutical ingredients.

11000

10,000 pieces/year

The tablet production line has large-scale production capacity, with a designed annual output of 1100 million tablets, enabling efficient production and delivery of various tablet products.

11000

10,000 pieces/year

The designed annual production capacity of the capsule production line is 1100 million capsules, enabling mass production of capsule medications and ensuring stable supply in clinical and market contexts.

1800

10,000 bags/year

The particle formulation production line is designed to have an annual capacity of 18 million bags, primarily used for the production of pharmaceutical particles, and can adapt flexibly to production needs of various particle specifications.

production equipment

Research and development equipmentBuild a solid foundation of quality

Haisco (Liaoning), Haisco (Sichuan), Haisco (Meishan), and Haisco (Shenyang all utilize joint production lines from advanced domestic and international manufacturers. The main production and inspection equipment comes from technologically advanced foreign manufacturers. This has achieved mechanization and automation in production. While ensuring product quality and compliance with GMP standards, it also meets advanced manufacturing processes more effectively.

Production Base

Global business layout

Haisco (Shenyang)

Shenyang Haisco Pharmaceutical Co., Ltd. was established in 2015. It is the core production base of Haisco Pharmaceutical Group's strategic layout in the Northeast region. The company has standardized office buildings, production facilities, and supporting infrastructure that have passed national GMP certification. It also has three sterile product production workshops, including lines for large-volume injectables (glass vials, non-PVC multi-layer co-extruded soft bags) and small-volume injectables. Focusing on areas such as anesthesia and analgesia, and parenteral nutrition, the company has obtained 5 invention patents and 9 utility model patents. It has received production approvals for 3 products in 5 specifications, including the first Chinese 1-class innovative intravenous anesthetic—c环泊酚 injection, fat emulsion amino acids (17) glucose (11%) injection, and compound amino acid injection (18AA-VII) among its star products.

Haisco (Liaoning)

It has 9 professional production lines for small-volume injections, large-volume injections, frozen dry powder injections, and powder injections.

Hisicor (Beijing Office)

Beijing is Haisco's national clinical operations, policy coordination, medical strategy, and national marketing management center.

Haisco (Sichuan)

Haisco (Meishan)

Hisicore (Shanghai Office of R&D Center)

The Shanghai R&D center is the only large-scale macromolecular R&D platform of the group. It is responsible for the early discovery of biopharmaceuticals and CMC process development, addressing the gaps in the group's biologic pipeline, and laying out global cutting-edge biotherapy strategies.

Haisco (Tibet)

Tibet Haisco Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the group. Established in 2019, it combines drug research and development with production. It mainly produces tablets, granules, and hard capsules. It is the first modern chemical preparation production base in the Tibet Autonomous Region to be built and put into operation. Currently, it has a comprehensive production line for oral solid preparations with an annual output of 10,000 million tablets, focusing on the production of lapatanide fumarate tablets.